Asaf Maoz

506 total citations
24 papers, 269 citations indexed

About

Asaf Maoz is a scholar working on Oncology, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Asaf Maoz has authored 24 papers receiving a total of 269 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 9 papers in Pathology and Forensic Medicine and 7 papers in Immunology. Recurrent topics in Asaf Maoz's work include Genetic factors in colorectal cancer (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Ovarian cancer diagnosis and treatment (5 papers). Asaf Maoz is often cited by papers focused on Genetic factors in colorectal cancer (6 papers), Cancer Immunotherapy and Biomarkers (5 papers) and Ovarian cancer diagnosis and treatment (5 papers). Asaf Maoz collaborates with scholars based in United States, Japan and Germany. Asaf Maoz's co-authors include Michael J. Dennis, Joel K. Greenson, Koji Matsuo, Shinya Matsuzaki, Marcia A. Ciccone, Lynda D. Roman, Maximilian Klar, David J. Nusbaum, Shai Rosenberg and Anil K. Sood and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Cancer.

In The Last Decade

Asaf Maoz

21 papers receiving 266 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Asaf Maoz United States	9	114	72	61	53	48	24	269
Amy Joehlin‐Price United States	11	174 1.5×	71 1.0×	78 1.3×	62 1.2×	38 0.8×	30	418
Benjamin Bonhomme France	8	131 1.1×	45 0.6×	46 0.8×	44 0.8×	43 0.9×	15	261
Raimundas Meškauskas Lithuania	10	126 1.1×	81 1.1×	88 1.4×	107 2.0×	65 1.4×	23	370
Laura Matteucci Italy	6	141 1.2×	69 1.0×	58 1.0×	78 1.5×	62 1.3×	15	272
Masataka Takenaka Japan	9	96 0.8×	133 1.8×	42 0.7×	54 1.0×	67 1.4×	22	342
Ning‐Fu Peng China	12	150 1.3×	61 0.8×	30 0.5×	131 2.5×	65 1.4×	20	356
Doris Höflmayer Germany	13	84 0.7×	171 2.4×	28 0.5×	70 1.3×	62 1.3×	22	360
Binhao Huang China	9	135 1.2×	70 1.0×	42 0.7×	93 1.8×	72 1.5×	22	305
Amy Jamieson Canada	12	71 0.6×	61 0.8×	69 1.1×	86 1.6×	62 1.3×	39	401
Lindsey E. Minion United States	8	170 1.5×	142 2.0×	70 1.1×	90 1.7×	58 1.2×	15	438

Countries citing papers authored by Asaf Maoz

Since Specialization

Citations

This map shows the geographic impact of Asaf Maoz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Asaf Maoz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Asaf Maoz more than expected).

Fields of papers citing papers by Asaf Maoz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Asaf Maoz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Asaf Maoz. The network helps show where Asaf Maoz may publish in the future.

Co-authorship network of co-authors of Asaf Maoz

This figure shows the co-authorship network connecting the top 25 collaborators of Asaf Maoz. A scholar is included among the top collaborators of Asaf Maoz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Asaf Maoz. Asaf Maoz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maoz, Asaf, Ronald Bleday, Jeffrey D. Goldsmith, et al.. (2025). Intratumoral Heterogeneity of Mismatch Repair Status and Outcome of Treatment With Dostarlimab in a Patient With Locally Advanced Rectal Adenocarcinoma. JCO Precision Oncology. 9(9). e2500041–e2500041. 1 indexed citations

Maoz, Asaf, Leah H. Biller, Marios Giannakis, et al.. (2025). Causes of Death Among Individuals With Lynch Syndrome in the Immunotherapy Era. JCO Precision Oncology. 9(9). e2500700–e2500700.

Whitfield, Troy W., Asaf Maoz, Dian Yang, et al.. (2024). Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction. Journal of Clinical Investigation. 134(9). 8 indexed citations

Maoz, Asaf, et al.. (2024). Gastrointestinal Cancer Precursor Conditions and Their Detection. Hematology/Oncology Clinics of North America. 38(4). 783–811. 1 indexed citations

Maoz, Asaf & Matthew B. Yurgelun. (2024). Leveraging Electronic Health Record Data to Understand Gaps Underlying the Underdiagnosis of Lynch Syndrome. JCO Clinical Cancer Informatics. 8(8). e2400032–e2400032.

Florou, Vaia, Charalampos S. Floudas, Asaf Maoz, et al.. (2023). Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden. Journal for ImmunoTherapy of Cancer. 11(8). e007440–e007440. 9 indexed citations

Tsai, Ya-Yu, Chenxu Qu, Joseph D. Bonner, et al.. (2023). Heterozygote advantage at HLA class I and II loci and reduced risk of colorectal cancer. Frontiers in Immunology. 14. 1268117–1268117. 3 indexed citations

Maoz, Asaf, et al.. (2022). 189P IL-10 enhances macrophage phagocytosis of cancer cells in response to CD47 blockade and opsonizing antibodies. Immuno-Oncology Technology. 16. 100301–100301.

Maoz, Asaf, Yusuke Koga, Adam C. Gower, et al.. (2021). Elevated T cell repertoire diversity is associated with progression of lung squamous cell premalignant lesions. Journal for ImmunoTherapy of Cancer. 9(9). e002647–e002647. 4 indexed citations

10.

Naqash, Abdul Rafeh, Charalampos S. Floudas, Asaf Maoz, et al.. (2021). STK11/TP53 co-mutated non-small cell lung cancer (NSCLC) to display a unique tumor microenvironment (TME) and metabolic profile.. Journal of Clinical Oncology. 39(15_suppl). 9087–9087. 3 indexed citations

11.

Ciccone, Marcia A., Teena Thakur, Charité Ricker, et al.. (2020). Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells. Gynecologic Oncology. 159(3). 869–876. 6 indexed citations

12.

Matsuo, Koji, Shinya Matsuzaki, David J. Nusbaum, et al.. (2020). Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer. Gynecologic Oncology. 160(1). 32–39. 23 indexed citations

13.

Maoz, Asaf, Koji Matsuo, Marcia A. Ciccone, et al.. (2020). Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord–Stromal Tumors: A Contemporary Review. Cancers. 12(6). 1398–1398. 25 indexed citations

14.

Weitzel, Jeffrey N., Susan L. Neuhausen, Aaron W. Adamson, et al.. (2019). Pathogenic and likely pathogenic variants in PALB2 , CHEK2 , and other known breast cancer susceptibility genes among 1054 BRCA ‐negative Hispanics with breast cancer. Cancer. 125(16). 2829–2836. 36 indexed citations

15.

Batalini, Felipe, et al.. (2019). Haemodialysis-associated thrombocytopenia: interactions among the immune system, membranes and sterilisation methods. BMJ Case Reports. 12(9). e229594–e229594. 2 indexed citations

16.

Maoz, Asaf, Michael J. Dennis, & Joel K. Greenson. (2019). The Crohn's-Like Lymphoid Reaction to Colorectal Cancer-Tertiary Lymphoid Structures With Immunologic and Potentially Therapeutic Relevance in Colorectal Cancer. Frontiers in Immunology. 10. 1884–1884. 44 indexed citations

17.

Maoz, Asaf, Marcia A. Ciccone, Shinya Matsuzaki, Robert L. Coleman, & Koji Matsuo. (2019). Emerging serine-threonine kinase inhibitors for treating ovarian cancer. Expert Opinion on Emerging Drugs. 24(4). 239–253. 9 indexed citations

18.

Ciccone, Marcia A., et al.. (2016). Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature. Expert Opinion on Investigational Drugs. 25(7). 781–796. 12 indexed citations

19.

Ciccone, Marcia A., Cora A. Ricker, Julie O. Culver, et al.. (2016). Inactivation of the Tumor Suppressor BRCA1 Interacting Protein C-terminal Helicase 1 (BRIP1) Gene Confers Increased Susceptibility to Platinum Antineoplastic Agents and Augments the Synergistic Response to Poly (ADP-ribose) Polymerase (PARP) Inhibition in Ovarian Epithelial Cells. Gynecologic Oncology. 143(1). 196–196. 1 indexed citations

20.

Maoz, Asaf, Shai Rosenberg, & Ronen R. Leker. (2015). Increased High-Sensitivity Troponin-T Levels Are Associated with Mortality After Ischemic Stroke. Journal of Molecular Neuroscience. 57(2). 160–165. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact